Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1978853 | 0.93 | HTR1A (0.39) | HTR1AKCNH2GRM5ESR1ESR2 | |
| SCHEMBL1980008 | 0.81 | HTR1A (0.38) | HTR1AKCNH2GRM5SMYD3GPR119 | |
| SCHEMBL1980422 | 0.78 | NPC1 (0.45) | HTR1ADRD2DRD3 | |
| SCHEMBL1979431 | 0.78 | HPGD (0.51) | TYR | |
| SCHEMBL12593455 | 0.76 | TYR (0.36) | PDK2TYRDRD2DRD3 | |
| SCHEMBL1982673 | 0.76 | LMNA (0.50) | TYRDRD2 | |
| SCHEMBL6436708 | 0.74 | TYR (0.45) | ESR1ESR2OPRD1OPRK1TYR | |
| SCHEMBL70722 | 0.74 | ALDH1A1 (0.46) | ESR1ESR2TYR | |
| SCHEMBL5935862 | 0.74 | ALDH1A1 (0.46) | ESR1ESR2TYR | |
| SCHEMBL19892266 | 0.74 | ALDH1A1 (0.46) | ESR1ESR2TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509945-B1 | 4-(AZACYCLOALKYL)-BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RES & DEV (FR) | 2014-03-05 | — | — | EP | claimed |
| US-20120323012-A1 | 4-(AZACYCLOALKYL) -BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-12-20 | — | — | US | claimed |
| EP-2509945-A1 | 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | Galderma Research & Development (FR) | 2012-10-17 | — | — | EP | claimed |
| WO-2011070080-A1 | 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-06-16 | — | — | WO | claimed |
| EP-2509945-B1 | 4-(AZACYCLOALKYL)-BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RES & DEV (FR) | 2014-03-05 | — | — | EP | disclosed |
| US-20120323012-A1 | 4-(AZACYCLOALKYL) -BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-12-20 | — | — | US | disclosed |
| EP-2509945-A1 | 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | Galderma Research & Development (FR) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011070080-A1 | 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323012-A1 | 4-(AZACYCLOALKYL) -BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | TYR, DDT, TH | HTR1A 2399/4885KCNH2 3769/4885GRM5 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.